Johnson & Johnson (NYSE:JNJ) Shares Sold by Atlantic Trust LLC

Atlantic Trust LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 12.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,967 shares of the company’s stock after selling 3,128 shares during the period. Johnson & Johnson accounts for approximately 2.7% of Atlantic Trust LLC’s portfolio, making the stock its 9th biggest holding. Atlantic Trust LLC’s holdings in Johnson & Johnson were worth $4,135,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in JNJ. Stevens Capital Management LP boosted its stake in shares of Johnson & Johnson by 87.9% during the 2nd quarter. Stevens Capital Management LP now owns 12,320 shares of the company’s stock worth $2,030,000 after acquiring an additional 5,763 shares in the last quarter. Kentucky Retirement Systems purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $25,262,000. Bank of Nova Scotia raised its stake in shares of Johnson & Johnson by 28.3% during the second quarter. Bank of Nova Scotia now owns 1,102,325 shares of the company’s stock valued at $181,597,000 after purchasing an additional 243,435 shares during the period. Bank of Montreal Can boosted its position in Johnson & Johnson by 22.0% in the 2nd quarter. Bank of Montreal Can now owns 7,072,870 shares of the company’s stock valued at $1,162,495,000 after buying an additional 1,276,479 shares during the last quarter. Finally, Quest Investment Management LLC raised its position in shares of Johnson & Johnson by 195.3% in the 2nd quarter. Quest Investment Management LLC now owns 92,207 shares of the company’s stock valued at $15,190,000 after purchasing an additional 60,984 shares in the last quarter. Hedge funds and other institutional investors own 67.29% of the company’s stock.

Shares of NYSE:JNJ traded down $0.43 during trading on Monday, hitting $163.93. 62,098 shares of the company were exchanged, compared to its average volume of 7,089,997. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $133.65 and a 1-year high of $179.92. The business’s 50 day moving average is $171.71 and its 200-day moving average is $167.61. The company has a market capitalization of $431.54 billion, a P/E ratio of 24.72, a price-to-earnings-growth ratio of 2.23 and a beta of 0.71.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 20th. The company reported $2.48 EPS for the quarter, topping the consensus estimate of $2.29 by $0.19. The company had revenue of $23.31 billion during the quarter, compared to the consensus estimate of $22.54 billion. Johnson & Johnson had a net margin of 19.92% and a return on equity of 37.06%. The company’s quarterly revenue was up 27.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.67 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 9.65 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 7th. Investors of record on Tuesday, August 24th were given a dividend of $1.06 per share. The ex-dividend date of this dividend was Monday, August 23rd. This represents a $4.24 annualized dividend and a yield of 2.59%. Johnson & Johnson’s payout ratio is currently 52.80%.

JNJ has been the topic of a number of research reports. SVB Leerink reissued a “buy” rating on shares of Johnson & Johnson in a report on Thursday, July 29th. Morgan Stanley downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price objective on the stock. in a research note on Tuesday, September 7th. Finally, Credit Suisse Group set a $193.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, June 7th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Buy” and an average price target of $190.38.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More: Why are analyst ratings important in trading stocks?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.